Advancing High-Throughput Proteomics with FTMS: Bruker Daltonics Announces Collaboration to Develop Highly Sensitive Protein Analysis Methods with Ultra-high Field FTMS.Business Editors/Health/Medical Writers BIOWIRE2K BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 27, 2003 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) today announced a collaboration with Mayo Clinic in the field of proteomics that will focus on the development of novel, more efficient methods for protein analysis using Fourier transform mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. (FTMS See Fusion FTMS. ). Proteomics looks at the function and role of proteins in healthy as well as disease states. Mass spectrometry plays a central role in identifying and quantifying proteins in cells and biological fluids (e.g., serum) providing insights into the biological basis of disease. The comprehensiveness in which a proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. can be measured is technologically challenging due to the sheer number of proteins, many of which are present at low concentrations. In contrast to genes, proteins cannot be amplified in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and therefore only minute amounts are available for detailed analysis. Thus, the development of high-end protein analysis instrumentation that can provide better sensitivity, peak capacity and throughput which will be critical for progress in proteomic research. The objective of the collaboration between Dr. David Muddiman, Director of the W.M. Keck FT-ICR Mass Spectrometry Laboratory at the Mayo Clinic, and Bruker Daltonics is to further develop the applications of ultra-high field FTMS toward the area of proteomics research. A modified Bruker Daltonics APEX(R) FTMS system, equipped with a 9.4 Tesla superconducting magnet, has already previously been used at the DOE Pacific Northwest National Laboratory The Pacific Northwest National Laboratory (PNNL) is one of nine United States Department of Energy (DOE) multiprogram national laboratories. The laboratory PNNL is located in Richland, Washington, and operates a marine research facility in Sequim, Washington. to characterize a bacterial proteome in just 3 hours using accurate mass measurements and automated MS/MS MS/MS Tandem Mass Spectroscopy MS/MS Multistage Mass Spectrometry . As part of the collaboration, Bruker Daltonics is now providing Mayo Clinic with the world's first commercial 12 Tesla FTMS system, optimized for proteome-wide measurements. The installation began today with the 12 Tesla superconducting magnet, and is scheduled to be completed in March 2003. The 12 Tesla APEX FTMS system at Mayo Clinic will act as Mayo's primary technology for unraveling the human proteome as defined in cells and biological fluids (e.g., serum, cerebral spinal fluid). The ultra-high field APEX system will be capable of ultra-high mass accuracy (less than 1 ppm mass errors), resolving power, wide dynamic range, and automated data-dependent MS/MS; the latter allows detailed proteome characterization when coupled to on-line multidimensional liquid chromatography. This unique and novel instrumentation will further strengthen Mayo's research activities in proteomics, essential for the understanding of the molecular basis of disease. Dr. Muddiman said: "Our development of this ultra-high resolving power FTMS approach will help unravel the entire human proteome - an estimated 25,000 proteins are expressed in a complex cell (e.g., nerve) while biological fluids are expected to contain 10,000. Proteolysis proteolysis Process in which a protein is broken down partially, into peptides, or completely, into amino acids, by proteolytic enzymes, present in bacteria and in plants but most abundant in animals. of a complex cell will generate over a million peptides, and that does not include post-translation modifications." He continued: "There is simply nothing like ultra-high field FTMS anywhere else - this technology allows us to approach mammalian proteomes with confidence. The application of FTMS technology directed solely at clinical problems is unique to Mayo and it will clearly advance molecular medicine, both at the basic-science and the patient-care levels." "We are extremely pleased that Dr. Muddiman has chosen to add the world's first 12 Tesla APEX to their suite of proteomics tools", stated Dr. Paul Speir, Asst. Vice President at Bruker Daltonics. "The research approach that Dr. Muddiman is taking nicely leverages the benefits of ultra-high field FTMS for proteomics research, and validates our long-standing commitment to the development of ultra-high field bio-analytical FTMS." About Mayo Clinic and Dr. David Muddiman Mayo Clinic is a not-for-profit healthcare organization based in Rochester, Minnesota. Its mission is to provide the best care to every patient every day through integrated clinical practice, education and research. The Mayo Proteomics Research Center (MPRC MPRC Multipurpose Range Complex MPRC Mobile Phone Repair Company (UK) MPRC Mayday Pain Resource Center MPRC Medicinal Plant Research Center MPRC Manpower & Personnel Readiness Center ) supports research programs of clinical investigators and career scientists engaged in the study of proteins for differential and functional proteomics initiatives. The skilled staff of the facility provide many services in protein chemistry, which include electrophoresis, liquid chromatography, protein sequencing, mass spectrometry, peptide mapping, solid phase peptide synthesis, protein structure prediction Protein structure prediction is one of the most important goals pursued by bioinformatics and theoretical chemistry. Its aim is the prediction of the three-dimensional structure of proteins from their amino acid sequences, sometimes including additional relevant information such as , and molecular modeling. Dr. David Muddiman, Director of the W.M. Keck FT-ICR Mass Spectrometry Laboratory in the MPRC, has extensive experience in developing novel methods for peptide and protein quantification, determining post-translational modifications of proteins, and analysis of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. using Fourier Transform Mass Spectrometry (FTMS) and has applied these methods to elucidate predicative biomarkers in serum, genotyping polymorphisms, allele frequency determination for SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily loci, and studies of anti-cancer drug-DNA interactions. About Bruker Daltonics Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com Cautionary Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion